Evolocumab appears to be equally effective at reducing LDL cholesterol and preventing cardiovascular events regardless of a patient’s kidney function, according to a new subanalysis of the FOURIER outcomes study presented at the American Society of Nephrology’s annual Kidney Week in San Diego.
Having reduced cardiorespiratory fitness (CRF) is as harmful to survival as coronary artery disease, smoking cigarettes or diabetes, suggests a retrospective study published Oct. 19 in JAMA Network Open.
Bariatric surgery may help reduce cardiovascular events beyond normal treatment with medication and lifestyle modifications for patients with severe obesity and type 2 diabetes, suggests an observational study published in JAMA.
Children who eat breakfasts high in energy but low in nutrition are likely to see higher cholesterol levels, increased insulin resistance and an elevated risk for cardiovascular complications in the future, according to research out of Spain.
Three men with type 2 diabetes used intermittent fasting to lose weight, lower their blood sugar levels and reverse their dependence on insulin treatment, according to a case study report published in The BMJ.
The deal Regeneron and Sanofi cut with Express Scripts to lower the prices of their PCSK9 inhibitor in exchange for simpler preauthorization forms has opened the floodgates for another two dozen such deals for the cholesterol-lowering drug class, the New York Times reported.